CODX
Co-Diagnostics, Inc.
There isn't enough reported data to score CODX yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
CODX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
CODX's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CODX PE Valuation
CODX has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CODX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect CODX's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CODX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$22.88 | +$6.82 |
| Q2 2026 | -$26.67 | +$7.83 |
| Q1 2026 | -$32.11 | +$2.99 |
| Q4 2025 | -$35.25 | +$1.95 |
| Q3 2025 | -$29.70 | +$11.40 |
| Q2 2025 | -$34.50 | +$3.00 |
| Q1 2025 | -$35.10 | +$4.20 |
| Q4 2024 | -$37.20 | -$1.20 |
CODX is still losing money, but less than at its worst: $22.88 per share over the past year, against $41.40 at its worst in late 2023.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CODX on earnings quality, reporting a profit while its opponent remains loss making.
CODX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $282.9K | +95% |
| Q2 2026 | $166.1K | +2% |
| Q1 2026 | $146K | +190% |
| Q4 2025 | $263.9K | +77% |
| Q3 2025 | $145.4K | -77% |
| Q2 2025 | $162.9K | -94% |
| Q1 2025 | $50.3K | -89% |
| Q4 2024 | $149.3K | -96% |
CODX's revenue is recovering but still below its 2021 peak: $282,881 last quarter, up 95% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2216% | +2608 points |
| Q2 2026 | -3732% | +1214 points |
| Q1 2026 | -6309% | +10701 points |
| Q4 2025 | -10057% | -2083 points |
| Q3 2025 | -4824% | -3228 points |
| Q2 2025 | -4946% | -4657 points |
| Q1 2025 | -17010% | -14817 points |
| Q4 2024 | -7974% | -7641 points |
CODX's operating margin was −2216% last quarter, up 2608 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CODX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CODX on profitability, with a higher operating margin.
CODX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.7M | +$280.7K |
| Q2 2026 | -$7.2M | +$1.5M |
| Q1 2026 | -$8M | +$848.8K |
| Q4 2025 | -$6.3M | +$2M |
| Q3 2025 | -$6M | +$1.4M |
| Q2 2025 | -$8.7M | -$3.4M |
| Q1 2025 | -$8.8M | +$55.5K |
| Q4 2024 | -$8.3M | -$3.1M |
CODX has burned cash in most quarters: −$27M over the past year, against −$32M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CODX on cash generation, producing positive trailing cash flow while its opponent burns cash.
CODX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +46% | +2M shares |
| 1 year | +468% | +5.2M shares |
| 3 years | +547% | +5.3M shares |
| 5 years | +533% | +5.3M shares |
| Available history | +725% | +5.5M shares |
CODX has 6M diluted shares, up 468% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | $159,673 |
| Q3 2023 | $166,326 |
| Q2 2023 | $555,734 |
| Q1 2023 | $482,196 |
| Q4 2022 | $1.2M |
| Q3 2022 | $10.4M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over CODX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CODX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -7.7x | Net Cash |
| Q2 2022 | -2.8x | Net Cash |
| Q1 2022 | -2.1x | Net Cash |
| Q4 2021 | -1.9x | Net Cash |
| Q3 2021 | -1.6x | Net Cash |
| Q2 2021 | -1.4x | Net Cash |
| Q1 2021 | -1.1x | Net Cash |
| Q4 2020 | -1.0x | Net Cash |
CODX has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CODX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.5 | Neutral |
| Stochastic | 0.9 | Oversold |
CODX's weekly RSI is 34 (neutral) and its Stochastic is 1 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CODX PE vs Healthcare Sector
| Metric | CODX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CODX has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CODX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.67 | 60% below |
| 20 week MA | $1.28 | 79% below |
| 50 week MA | $2.84 | 90% below |
| 100 week MA | $7.77 | 97% below |
| 200 week MA | $24.5 | 99% below |
CODX is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CODX on trend strength, trading above more of its moving averages.
CODX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $27.8 | $325.2 | +1069% |
| 2021 | $325.2 | $282.3 | -13% |
| 2022 | $282.3 | $76.5 | -73% |
| 2023 | $76.5 | $39.9 | -48% |
| 2024 | $39.9 | $21.9 | -45% |
| 2025 | $21.9 | $7.05 | -68% |
| 2026 YTD | $7.05 | $0.27 | -96% |
CODX has finished five years in a row lower, and it's down 96% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CODX on returns for 2026, with the stronger performance.